Development & Evaluation of Monoaminergic Agonist PET Tracers Table of Contents
نویسندگان
چکیده
Introduction: R-[C]-SKF 82957 is a high-affinity and potent dopamine D1 receptor agonist radioligand, which gives rise to a brainpenetrant lipophilic metabolite. In this study, we demonstrate that systemic administration of catechol-O-methyl transferase (COMT) inhibitors blocks this metabolic pathway, facilitating the use of R-[C]-SKF 82957 to image the high-affinity state of the dopamine D1 receptor with PET. Methods: R-[C]SKF 82957 was administered to untreated and COMT inhibitor-treated conscious rats, and the radioactive metabolites present in the brain and plasma were quantified by HPLC. Under optimal conditions, cerebral uptake and dopamine D1 binding of R-[ C] SKF 82957 were measured ex vivo. In addition, pharmacological challenges with the receptor antagonist SCH 23390, amphetamine, the dopamine reuptake inhibitor RTI-32 and the dopamine hydroxylase inhibitor α-methyl-p-tyrosine were performed to study the specificity and sensitivity of R-[C]-SKF 82957 dopamine D1 binding in COMT-inhibited animals. Results: Treatment with the COMT inhibitor tolcapone was associated with a dose-dependent (EC90 5.3±4.3 mg/kg) reduction in the lipophilic metabolite. Tolcapone treatment (20 mg/kg) also resulted in a significant increase in the striatum/cerebellum ratio of R-[C]SKF 82957, from 15 (controls) to 24. Treatment with the dopamine D1 antagonist SCH 23390 reduced the striatal binding to the levels of the cerebellum, demonstrating a high specificity and selectivity of R-[C]SKF 82957 binding. Conclusions: Pre-treatment with the COMT inhibitor tolcapone inhibits formation of an interfering metabolite of R-[C]SKF 82957. Under such conditions, R-[C]SKF 82957 demonstrates high potential as the first agonist radiotracer for imaging the dopamine D1 receptor by PET. © 2010 Elsevier Inc. All rights reserved.
منابع مشابه
The application of unconventional PET tracers in nuclear medicine
The production and application of PET tracers has been a unique step in the progress of nuclear medicine in last two decades. The most important PET tracers include F-18, C-11 and N-13 radioisotopes and many nuclear medicine centers throughout the globe are using them. However some new tracers are under their way to the mass administration, currently being in th...
متن کاملSynthesis and evaluation in rats of homologous series of [F]-labeled dopamine D2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers
Background: Agonist positron emission tomography (PET) tracers for dopamine D2/3 receptors (D2/3Rs) offer greater sensitivity to changes in endogenous dopamine levels than D2/3R antagonist tracers. D2/3R agonist tracers currently available for clinical research are labeled with the short-lived isotope carbon-11, which limits their use. We aimed to develop high-affinity D2R agonists amenable for...
متن کاملSynthesis and evaluation in rats of homologous series of [18F]-labeled dopamine D2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers
BACKGROUND Agonist positron emission tomography (PET) tracers for dopamine D2/3 receptors (D2/3Rs) offer greater sensitivity to changes in endogenous dopamine levels than D2/3R antagonist tracers. D2/3R agonist tracers currently available for clinical research are labeled with the short-lived isotope carbon-11, which limits their use. We aimed to develop high-affinity D2R agonists amenable for ...
متن کاملIssues pertaining to PET imaging of liver cancer
Positron emission tomography (PET) imaging using 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) has proven valuable in the diagnosis, staging and restaging for many cancers. However, its application for liver cancer has remained limited owing in part to the relatively high background uptake of the tracer in the liver plus the significant variability of the tumor specific uptake in liver cancer among pa...
متن کاملNew protein deposition tracers in the pipeline
Traditional nuclear medicine ligands were designed to target cellular receptors or transporters with a binding pocket and a defined structure-activity relationship. More recently, tracers have been developed to target pathological protein aggregations, which have less well-defined structure-activity relationships. Aggregations of proteins such as tau, α-synuclein, and β-amyloid (Aβ) have been i...
متن کامل